Importantly, in vivo administration of the new NAMPT inhibitors as a single agent prevented and/or delayed tumor growth in an animal model of human Burkitt lymphoma and significantly prolonged median survival, thereby underlining the therapeutic potential of these molecules. Here, NAMPT is linked to Burkitt lymphoma.